AVR 1.01% $10.75 anteris technologies ltd

I think that you'll find that Cardiocel 3d is already...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 316 Posts.
    lightbulb Created with Sketch. 4
    I think that you'll find that Cardiocel 3d is already specifically targeting neonatal patients:

    From announcement on 2 May:

    As there are virtually no flat surfaces in the vascular or cardiac structure, this unique 60 shaped collagen product targets complex neonatal arch and pulmonary artery repair and is intended to help optimize suturing of central and extra-cardiac shunts. Its dimensions and specifications are designed to ‘mate’ with the triple plane anatomy found in neonatal arch and pulmonary artery repairs.

    I suspect that feasability studies to control thickness could also address the study results, as described in the webinar presentation:

    § Control of ADAPT® scaffold thickness:
    First automated machine prototype complete
    Processed a pericardium sheet from .5mm to .3mm
    Processed a porton of a pericardium sheet as low as .15mm
    Capability to produce two different thickness levels in same sheet


    exee
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
(20min delay)
Last
$10.75
Change
-0.110(1.01%)
Mkt cap ! $227.2M
Open High Low Value Volume
$10.95 $10.95 $10.24 $285.2K 26.69K

Buyers (Bids)

No. Vol. Price($)
1 1000 $10.49
 

Sellers (Offers)

Price($) Vol. No.
$10.75 413 1
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.